Patterns of Mortality After Prolonged Follow-up of a Randomised Controlled Trial Using Granulocyte Colony-Stimulating Factor to Maintain Chemotherapy Dose Intensity in Non-Hodgkin’s Lymphoma
Br J Cancer. 2008 Aug 22;99(2):253-258, AR Clamp, WD Ryder, S Bhattacharya, R Pettengell, JA Radford
TAKE-HOME MESSAGE
Abstract
Abstract
The effect of utilising granulocyte colony-stimulating factor (G-CSF) to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma (NHL) on long-term mortality patterns has not been formally evaluated. We analysed prolonged follow-up data from the first randomised controlled trial investigating this approach. Data on 10-year overall survival (OS), progression-free survival (PFS), freedom from progression (FFP) and incidence of second malignancies were collected for 80 patients with aggressive...
SUMMARY
OncologySTAT Editorial Team
Myelosuppression and increased susceptibility to infection limit the dosages of cytotoxic chemotherapies used in patients with non-Hodgkin’s lymphoma (NHL). To reduce the incidence of these toxicities and thereby maintain dose intensity of chemotherapy, patients often receive adjunctive therapy with hematologic colony-stimulating factors, such as granulocyte colony-stimulating factor (G-CSF). A meta-analysis of previous studies of G-CSF use in patients with NHL showed a 26% reduced risk of febrile...
